← Leaderboards
Jonathan M Kurie
University Of Tx Md Anderson Can Ctr
$24,221,061
Attributed
$24,221,061
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,221,061 · 15
By mechanism
R01$22,237,631 · 12
P50$1,983,430 · 2
P01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Houfu Guo$2,060,866
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungMutantTumorCellsMutationLung NeoplasmsLung AdenocarcinomaLungCancer CellAdenocarcinoma CellAllelesMouse ModelBaseCancer PatientNeoplastic CellNeoplasm MetastasisMediator Of Activation ProteinClinical TrialsPropertyMediatingEpithelialGenesEpithelial CellsPhosphotransferases
Grant awards (91)
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2$551,809
R01 · FY2025 · CA · contact PI
A pro-metastatic secretory pathway activated by p53 loss in lung cancer$542,703
R01 · FY2025 · CA · contact PI
A pro-metastatic secretory pathway activated by p53 loss in lung cancer$530,294
R01 · FY2024 · CA · contact PI
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2$524,219
R01 · FY2024 · CA · contact PI
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi$421,158
R01 · FY2024 · CA · contact PI
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2$527,923
R01 · FY2023 · CA · contact PI
A pro-metastatic secretory pathway activated by p53 loss in lung cancer$467,592
R01 · FY2023 · CA · contact PI
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi$434,457
R01 · FY2023 · CA · contact PI
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2$527,918
R01 · FY2022 · CA · contact PI
A pro-metastatic secretory pathway activated by p53 loss in lung cancer$425,258
R01 · FY2022 · CA · contact PI
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi$414,865
R01 · FY2022 · CA · contact PI
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2$554,196
R01 · FY2021 · CA · contact PI
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi$450,366
R01 · FY2021 · CA · contact PI
A pro-metastatic secretory pathway activated by p53 loss in lung cancer$433,936
R01 · FY2021 · CA · contact PI
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus$366,000
R01 · FY2021 · CA · contact PI
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi$460,592
R01 · FY2020 · CA · contact PI
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus$366,000
R01 · FY2020 · CA · contact PI
Targeting Anaphase Catastrophe to Combat Lung Cancer$355,432
R01 · FY2019 · CA · contact PI
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus$352,323
R01 · FY2019 · CA · contact PI
Regulation of Lung Cancer Metastasis by a Procollagen Lysine Hydroxylase$297,281
R01 · FY2019 · CA · contact PI
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus$376,867
R01 · FY2018 · CA · contact PI
Targeting Anaphase Catastrophe to Combat Lung Cancer$366,425
R01 · FY2018 · CA · contact PI
Regulation of Lung Cancer Metastasis by ZEB1$331,805
R01 · FY2018 · CA · contact PI
Regulation of Lung Cancer Metastasis by a Procollagen Lysine Hydroxylase$306,476
R01 · FY2018 · CA · contact PI
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatus$378,946
R01 · FY2017 · CA · contact PI
Regulation of Lung Cancer Metastasis by ZEB1$331,805
R01 · FY2017 · CA · contact PI
Regulation of Lung Cancer Metastasis by a Procollagen Lysine Hydroxylase$291,471
R01 · FY2017 · CA · contact PI
Regulation of Lung Cancer Metastasis by ZEB1$336,354
R01 · FY2016 · CA · contact PI
Regulation of Lung Cancer Metastasis by a Procollagen Lysine Hydroxylase$291,471
R01 · FY2016 · CA · contact PI
Regulation of Lung Cancer Metastasis by ZEB1$337,030
R01 · FY2015 · CA · contact PI
Regulation of Lung Cancer Metastasis by miR-200$329,792
R01 · FY2015 · CA · contact PI
Regulation of Lung Cancer Metastasis by a Procollagen Lysine Hydroxylase$321,491
R01 · FY2015 · CA · contact PI
Regulation of Lung Cancer Metastasis by ZEB1$337,030
R01 · FY2014 · CA · contact PI
Regulation of Lung Cancer Metastasis by miR-200$319,845
R01 · FY2014 · CA · contact PI
Regulation of Lung Cancer Metastasis by miR-200$305,245
R01 · FY2013 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$229,269
R01 · FY2013 · CA · contact PI
P-3: Targeting Tumor Microenvironment in NSCLC$55,592
P50 · FY2013 · CA · contact PI
Regulation of Lung Cancer Metastasis by miR-200$324,729
R01 · FY2012 · CA · contact PI
P-3: Targeting Tumor Microenvironment in NSCLC$250,764
P50 · FY2012 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$243,904
R01 · FY2012 · CA · contact PI
Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis$189,462
R01 · FY2012 · CA · contact PI
Regulation of Lung Cancer Metastasis by miR-200$339,229
R01 · FY2011 · CA · contact PI
Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis$255,440
R01 · FY2011 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$245,382
R01 · FY2011 · CA · contact PI
P-3: Targeting Tumor Microenvironment in NSCLC$238,299
P50 · FY2011 · CA · contact PI
Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis$62,001
R01 · FY2011 · CA · contact PI
Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis$263,340
R01 · FY2010 · CA · contact PI
Mediators of Oncogenic KRAS in Lung Adenocarcinoma$258,530
R01 · FY2010 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$251,447
R01 · FY2010 · CA · contact PI
P-3: Targeting Tumor Microenvironment in NSCLC$251,126
P50 · FY2010 · CA · contact PI
Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis$62,402
R01 · FY2010 · CA · contact PI
Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis$265,753
R01 · FY2009 · CA · contact PI
Mediators of Oncogenic KRAS in Lung Adenocarcinoma$258,530
R01 · FY2009 · CA · contact PI
P-3: Targeting Tumor Microenvironment in NSCLC$251,519
P50 · FY2009 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$251,447
R01 · FY2009 · CA · contact PI
Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis$279,182
R01 · FY2008 · CA · contact PI
Mediators of Oncogenic KRAS in Lung Adenocarcinoma$258,530
R01 · FY2008 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$234,808
R01 · FY2008 · CA · contact PI
P-3: Targeting Tumor Microenvironment in NSCLC$209,773
P50 · FY2008 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$58,532
R01 · FY2008 · CA · contact PI
Mediators of Oncogenic KRAS in Lung Adenocarcinoma$258,530
R01 · FY2007 · CA · contact PI
PI3K pathway in lung cancer prevention and therapy$242,119
P50 · FY2007 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$234,808
R01 · FY2007 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$53,063
R01 · FY2007 · CA · contact PI
Mediators of Oncogenic KRAS in Lung Adenocarcinoma$266,250
R01 · FY2006 · CA · contact PI
PI3K pathway in lung cancer prevention and therapy$242,119
P50 · FY2006 · CA · contact PI
Kinase Signaling in Lung Tumorigenesis$241,820
R01 · FY2006 · CA · contact PI
IGFBP 6--A Target in Lung Cancer Prevention$230,699
R01 · FY2006 · CA · contact PI
RETINOID SIGNALING IN NEW LUNG CANCER PREVENTION MODELS$284,667
R01 · FY2005 · CA
Kinase Signaling in Lung Tumorigenesis$247,640
R01 · FY2005 · CA
IGFBP 6--A Target in Lung Cancer Prevention$236,250
R01 · FY2005 · CA
RETINOID SIGNALING IN NEW LUNG CANCER PREVENTION MODELS$287,972
R01 · FY2004 · CA
Kinase Signaling in Lung Tumorigenesis$247,640
R01 · FY2004 · CA
IGFBP 6--A Target in Lung Cancer Prevention$202,500
R01 · FY2004 · CA
IGFBP 6--A Target in Lung Cancer Prevention$270,000
R01 · FY2002 · CA
RETINOID SIGNALING IN NEW LUNG CANCER PREVENTION MODELS$236,250
R01 · FY2002 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2002 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2002 · CA
TRIAL OF CELECOXIB IN LUNG CANCER CHEMOPREVENTION$0
P01 · FY2002 · CA
RETINOID SIGNALING IN NEW LUNG CANCER PREVENTION MODELS$236,250
R01 · FY2001 · CA
IGFBP 6--A Target in Lung Cancer Prevention$202,500
R01 · FY2001 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2001 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2001 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2001 · CA
TRIAL OF CELECOXIB IN LUNG CANCER CHEMOPREVENTION$0
P01 · FY2001 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$242,119
P50 · FY2000 · CA
RETINOID SIGNALING IN NEW LUNG CANCER PREVENTION MODELS$202,500
R01 · FY2000 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2000 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2000 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2000 · CA
RETINOID PREVENTION OF LUNG CANCER IN FORMER SMOKERS$0
P50 · FY2000 · CA